Studien

Bereits durchgeführte Studien

Sponsor

Indikation

Prüfmedikament

Therapiedauer

Eli-Lilly Psoriasis Ixekizumab 18 Monate
BMS Psoriasis BMS-986165/Placebo 12 Wochen
CES ISC Cesra Follikulitis Ilon/Jod/Vaseline 1 Woche
R668-AD-1225 Regeneron Neurodermitis Dupilumab 3 Jahre
Janssen Psoriasis Guselkumab/Fumaderm 56 Wochen
Birch Allergieherapeutics Birkenpollenallergie PQBirch301/Placebo 1 Jahr
PM AllergyTherapeutics Hausstaubmilbenallergie PURETHAL/Placebo 1 Jahr
IMI C Dermapharm Aktinische Keratose Aldara/Placebo/Imiquimod 8 Wochen
RD Galderma Atopische Dermatitis Nemolizumab/Placebo+TCS 24 Wochen
Grass AllergyTherapeutics Gräserallergie Graspollen/Placebo 6 Wochen

Aufklärung bereits durchgeführte Studien

2015:

  1. Efficacy, safety and tolerability assessment of secukinumab 300 mg s.c. optimization in patients with moderate to severe chronic plaque psoriasis. EudraCT Nummer:2014-005339-15
  2. Clinical study to compare two creams with the active substance gentamicin and betamethason and one cream without active substance for patients with bacterial infected eczema. EudraCT Nummer: 2014-005518-44
  3. The purpose of this phase II placebo controlled study is to assess the safety and efficacy on conjunctival provocation test (CPT) of different short courses of PQ Birch treatment, as part of the clinical development programme of this product. EudraCT Nummer: -

2016:

  1. A 24-Week Multicenter, Randomized, Open-Label, Parallel Group Study Comparing the Efficacy and Safety of Ixekizumab to Fumaric Acid Esters and Methotrexate in Patients with Moderate-to-Severe Plaque Psoriasis who are Naive to Systemic Treatment. EudraCT Nummer: 2015-002649-69
  2. A study to assess the efficacy and safety of Dupilumab in patients with severe atopic dermatitis (AD) that are not controlled with oral cyclosporine A (CSA) or for those who cannot take oral CSA because it is not medically advisable. EudraCT Nummer: 2015-002653-35
  3. A study to confirm the efficacy and safety of different dupilumab dose regimens in adults with atopic dermatitis (AD) EudraCT Nummer: 2014-003384-38
  4. A study to assess the long-term safety of dupilumab administered in adult patients with atopic dermatitis (AD) EudraCT Nummer: 2013-001449-15
  5. A study of guselkumab for patients with moderate to severe plaque psoriasis EudraCT Nummer: 2016-002135-15

2017:

  1. Efficacy and Safety Trial of JNJ-54861911 in Participants who are Asymptomatic At Risk for Developing Alzheimer’s Dementia EudraCT Nummer: 2015-000948-42
  2. A Study of LY3314814 in Participants With Mild Alzheimer's Disease Dementia (Daybreak) EudraCT Nummer: 2015-005625-39
  3. Clinical study to compare two creams with the active substance imiquimod and one cream without active substance for patients with actinic keratosis EudraCT Nummer: 2016-000712-15
  4. A multi-centre, randomized, two-armed, parallel group and evaluator-blinded study of efficacy and safety of topical MOB015B in the treatment of mild to moderate distal subungual onychomycosis (DSO ) EudraCT Nummer: 2016-001204-39
  5. A multi-centre study of the efficacy and safety of PQBirch [PQBirch301] EudraCT Nummer: 2016-002781-31
  6. A clinical study where patients will receive either a new medication (grass pollen -ASIT+TM of gpASIT+TM) or placebo (an inert substance) to treat patients with grass pollen-induced allergic rhinoconjunctivitis. Both products will administered in a subcutaneous way. EudraCT Nummer: 2015-002105-11
  7. Investigation of the effectiveness, tolerability and safety of ilon® Salbe classic in the treatment of acute inflammation of the hair follicle EudraCT Nummer: 2016-005105-39
    Untersuchung der Wirksamkeit, Verträglichkeit und Sicherheit von ilon® Salbe classic in der Behandlung von akuten Entzündungen der Haarfollikel
  8. A phase 4 trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate to severe plaque psoriasis EudraCT Nummer: 2016-003867-21
Daten werden übermittelt...

Ihre Nachricht wurde erfolgreich an uns übermittelt!

Wir werden die Anfrage schnellstmöglich bearbeiten.

Vielen Dank für Ihre Nachricht!
Ihr Studienzentrum Dr. Leitz & Kollegen

Bitte füllen Sie die rot umrandeten Felder korrekt aus.

Kontakt


Hiermit stimme ich folgenden Datenschutzbestimmungen zu: "Datenschutz / Schutz Ihrer Privatsphäre"

Senden